BIOMARKER-DRIVEN TREATMENT DECISION IN METASTATIC NSCLC

HALL 407
SINGAPORE

Chairs
Marina Garassino, Italy
Ross Soo, Singapore

FRIDAY, 22 NOVEMBER 2019
12:45 – 14:15

12:45 Introduction
Ross Soo, Singapore

12:50 Immune-checkpoints inhibitors (ICI) in non-oncogenic addicted mNSCLC
Marina Garassino, Milan, Italy

13:15 EGFR mutant mNSCLC: Single agent or in combination?
Patrice Barlesi, Marseille, France

13:40 Future development in the use of biomarkers
Ross Soo, Singapore

14:05 Conclusion
Marina Garassino, Milan, Italy

This educational activity is provided by ESMO and supported by Lilly Oncology.